Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity
Diabetes, Obesity and Metabolism · 2025-04 · 27 (4) · 2223-2231
DOI: 10.1111/dom.16223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.02.2025. Verfasst von SeongHo Jo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birm…. Hauptthemen laut MEDLINE: Obesity, Glucose Intolerance, Adiposity, Carrier Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Aims
Glucagon‐like peptide 1 receptor agonists and dual agonists have changed the treatment landscape of obesity and type 2 diabetes (T2D), but significant limitations have emerged due to their gastrointestinal side effects, loss of lean mass, and necessity for ongoing subcutaneous injections. Our objective was, therefore, to test a novel small molecule as a different and potentially better tolerated oral medications to improve obesity‐associated impairment in glucose homeostasis. Materials and Methods High‐fat diet (HFD)‐fed mice or severely obese, leptin‐deficient ob/ob mice were randomly assigned to serve as controls or receive oral TIX100, a novel thioredoxin‐interacting protein (TXNIP) inhibitor just approved by the FDA as an investigational new drug for type 1 diabetes (T1D). The TIX100 effects on glucose intolerance and weight control were then assessed.
Results
TIX100 protected against HFD‐induced glucose intolerance, hyperinsulinemia, and hyperglucagonemia. TIX100 also reduced diet‐induced adiposity resulting in 15% lower weight in treated mice as compared with controls on HFD ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Anath Shalev
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Jo, S., Jing, G., Chen, J., Xu, G., & Shalev, A. (2025). Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity. Diabetes, Obesity and Metabolism, 27(4), 2223-2231. https://doi.org/10.1111/dom.16223
Vancouver
Jo S, Jing G, Chen J, Xu G, Shalev A. Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity. Diabetes, Obesity and Metabolism. 2025;27(4):2223-2231. doi:10.1111/dom.16223
BibTeX
@article{Jo2025,
author = {Jo, SeongHo and Jing, Gu and Chen, Junqin and Xu, Guanlan and Shalev, Anath},
title = {Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {4},
pages = {2223--2231},
doi = {10.1111/dom.16223}
}
EUVIMED